What question did this study set out to answer?

The study aims to assess the efficacy of combining selinexor with ruxolitinib in treating myelofibrosis.

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription ( JAK / STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial investigates dual therapy of selinexor and ruxolitinib in myelofibrosis, indicating improved outcomes.

The study aims to assess the efficacy of combining selinexor with ruxolitinib in treating myelofibrosis.
Evaluated selinexor and ruxolitinib in MF models including JAK2 V617F and CALR mutant cell lines and patient samples.
Conducted multi-omic analyses to assess effects on nuclear retention and inflammatory signaling.
Assessed proliferation, colony formation, and secretion of inflammatory mediators from MF patient cells.
Combination therapy showed greater anti-proliferative activity compared to ruxolitinib alone.
Selinexor induced G1 arrest and apoptosis in ruxolitinib-resistant MPN cell lines.
Inhibition of NF-kB transcriptional activity and reduced secretion of TNFα, IL-6, and MCP-1 from patient cells.

Kashyap et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark